Achilles Therapeutics (NASDAQ:ACHL – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Earnings and Valuation
This table compares Achilles Therapeutics and MeiraGTx’s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Achilles Therapeutics | N/A | N/A | -$69.67 million | ($1.60) | -0.46 |
| MeiraGTx | $8.12 million | 33.49 | -$84.03 million | ($1.17) | -3.62 |
Achilles Therapeutics has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Achilles Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| MeiraGTx | 0 | 0 | 2 | 0 | 3.00 |
Achilles Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 447.95%. MeiraGTx has a consensus price target of $22.50, indicating a potential upside of 431.91%. Given Achilles Therapeutics’ higher possible upside, research analysts clearly believe Achilles Therapeutics is more favorable than MeiraGTx.
Institutional & Insider Ownership
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by company insiders. Comparatively, 8.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Achilles Therapeutics and MeiraGTx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Achilles Therapeutics | N/A | -42.95% | -37.88% |
| MeiraGTx | -651.19% | -122.82% | -48.11% |
Risk and Volatility
Achilles Therapeutics has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Summary
MeiraGTx beats Achilles Therapeutics on 7 of the 13 factors compared between the two stocks.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
